Form 4: BioMarin Pharmaceutical Inc. Officer Reports Stock Transactions

Erin Burkhart, GVP, Chief Accounting Officer of BioMarin Pharmaceutical Inc., reports the acquisition of restricted stock units and stock options, as well as the disposition of shares to cover tax obligations.

Summary

• On March 15, 2024, Erin Burkhart, GVP, Chief Accounting Officer of BioMarin Pharmaceutical Inc., acquired 4,720 shares of common stock through restricted stock units.
• On the same date, Burkhart was granted options to purchase 7,050 shares of common stock at an exercise price of $83.87, vesting in installments starting March 15, 2025.
• On March 18, 2024, Burkhart disposed of 372 shares of common stock at a price of $83.87 per share to satisfy tax obligations.
• Following these transactions, Burkhart directly owns 18,442 shares of BioMarin Pharmaceutical Inc. common stock and holds options for 7,050 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing reflects routine transactions related to executive compensation and tax obligations. There is no indication of positive or negative sentiment regarding the company's prospects.

Positives

• The acquisition of restricted stock units and stock options suggests confidence in the company's future performance.

Negatives

• The disposition of shares, while for tax obligations, slightly reduces Burkhart's direct holdings in the company.

Risks

• There are no specific risks mentioned in this document.
• However, insider transactions are always subject to scrutiny and could be interpreted negatively if not properly understood.

Future Outlook

There are no forward-looking statements in this document.

Industry Context

This filing is a routine disclosure of insider transactions, which is common for publicly traded companies like BioMarin in the pharmaceutical industry. It provides transparency regarding the holdings and transactions of company officers.

Comparison to Industry Standards

• Insider trading disclosures are standard practice for publicly listed companies and are governed by SEC regulations.
• The vesting schedule of the stock options is typical for executive compensation packages in the pharmaceutical industry, often designed to incentivize long-term performance.
• Comparable companies like Amgen, Gilead Sciences, and Vertex Pharmaceuticals also regularly report similar insider transactions.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders.
• Shareholders may view the insider transactions as a reflection of management's confidence in the company, but the impact is likely to be small.

Key Dates